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Abstract
Analysis of publicly available genomic and gene expression data demonstrates that MCL1 expression is frequently
elevated in breast cancer. Distinct from other pro-survival Bcl-2 family members, the short half-life of MCL-1 protein led
us to investigate MCL-1 protein expression in a breast cancer tissue microarray and correlate this with clinical data.
Here, we report associations between high MCL-1 and poor prognosis in speciﬁc subtypes of breast cancer including
triple-negative breast cancer, an aggressive form that lacks targeted treatment options. Deletion of MCL-1 in the
mammary epithelium of genetically engineered mice revealed an absolute requirement for MCL-1 in breast
tumorigenesis. The clinical applicability of these ﬁndings was tested through a combination of approaches including
knock-down or inhibition of MCL-1 to show triple-negative breast cancer cell line dependence on MCL-1 in vitro and
in vivo. Our data demonstrate that high MCL-1 protein expression is associated with poor outcome in breast cancer
and support the therapeutic targeting of MCL-1 in this disease.
Introduction
Breast cancer survival has increased in recent decades
due, in part, to the introduction of targeted therapies.
Development of these therapeutics has arisen from an
increased understanding of the diverse molecular char-
acteristics of breast tumours such as expression of
receptors for oestrogen, progesterone or ampliﬁcation of
human epidermal growth factor receptor 2 (HER2). For
example, hormonal therapies such as Tamoxifen have
efﬁcacy in breast cancers expressing the oestrogen
receptor (ER) while cancers with ERBB2 ampliﬁcation
(HER2) can be treated with HER2 targeting therapies such
as trastuzumab (e.g., Herceptin). However, resistance to
conventional cytotoxic drugs and to new targeted thera-
pies can emerge and despite dramatic improvements in
patient outcome, breast cancer remains the leading cause
of cancer mortality worldwide in females1.
Evasion of apoptosis promotes tumour development
and also acts as a barrier to cancer therapy-induced cell
death. Mitochondrial-dependent apoptosis is controlled
by Bcl-2 family members—these proteins control cell fate
by regulating mitochondrial integrity. During apoptosis,
upregulation of pro-apoptotic Bcl-2 members such as
BIM (so called BH3-only proteins) overwhelms anti-
apoptotic Bcl-2 function and activates BAX/BAK trig-
gering mitochondrial outer membrane permeabilisation
and cell death2. Aberrant increases in the level of anti-
apoptotic Bcl-2 proteins such as BCL-2, MCL-1 or BCL-
XL prevents apoptosis, this both promotes cancer and
allows resistance to cancer therapy-induced cell killing3.
Recent progress has been made in the development of
inhibitors of anti-apoptotic BCL-2 proteins with the aim
of restoring apoptosis in cancer4. Small molecules have
been developed, called BH3-mimetics that functionally
mimic BH3-only proteins, freeing pro-apoptotic Bcl-2
proteins to trigger or sensitize to cell death. The value of
such drugs has been highlighted in the treatment of
haematological malignancies where the BCL-2 targeting
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drug venetoclax has recently secured FDA approval for
use in some types of chronic lymphocytic leukaemia5,6.
Due to differential binding afﬁnities, various BH3-
mimetics display speciﬁcity for particular anti-apoptotic
BCL-2 proteins. BH3-mimetics targeting BCL-2/BCL-XL
have also shown promise in preclinical studies of solid
tumours, including breast, when used in combination
with docetaxel or tamoxifen7,8 but resistance can be
mediated by MCL-19,10. In addition to differential BH3-
binding properties, MCL-1 is distinguished by its short
protein half-life and ability to regulate mitochondrial
metabolism11,12. There has been intense activity to
develop BH3-mimetics to target MCL-1 with recent
progress; A1210477 shows impressive anti-cancer effects
in vitro on diverse cancer cell lines13,14; UMI-77 is effec-
tive as a single agent on pancreatic cancer cell lines
in vitro and in xenograft models15; and S63845 shows
tumour-speciﬁc cell killing in leukaemia, lymphoma and
myeloma in a variety of in vitro, xenograft and genetically
modiﬁed mouse models16. Encouragingly, tumour cells
seem particularly sensitive to MCL-1 inhibition suggest-
ing an adequate therapeutic window.
As well as playing a role in resistance to therapy, ele-
vated MCL-1 can actually drive haematopoietic tumour
development17. This oncogenic role for MCL-1 may be
widespread as the MCL1 locus is one of the most fre-
quently ampliﬁed regions of the human genome across a
wide variety of cancers including breast cancer18. Recent
evidence from in vitro experiments suggests an important
role for MCL-1 in breast cancer cell survival10,19,20, par-
ticularly in triple-negative (TN) breast cancers21–23 and
expression of a mutant form of BIM that speciﬁcally
interacts with MCL-1 inhibits metastases of TN breast
cancer cell lines in xenograft models24. TN breast cancers
are aggressive with poor patient prognosis and because
they lack expression of the ER and the progesterone
receptor (PR) and do not have ampliﬁcation of ERBB2,
they do not respond to current targeted therapies.
There is a need for new therapeutic options to reduce the
mortality burden of breast cancer. Given the emergence of
BH3-mimetic drugs capable of targeting MCL-1 we
investigated the expression and functional requirement for
MCL-1 in breast cancer, systematically testing this through
a combination of human breast tumour tissue analysis with
correlation to clinicopathological data; breast cancer cell
line testing in vitro and in vivo; and for the ﬁrst time show a
role for MCL-1 in mammary tumorigenesis using a
genetically engineered mouse model.
Results
High MCL-1 protein expression predicts poor outcome in
breast cancer
As ampliﬁcation of the MCL1 locus is frequently
observed in a range of cancer types18 we investigated the
frequency of elevated MCL1 in breast cancer. Analysis of
comprehensive, publically available data reveals that
MCL1 gene ampliﬁcation and/or mRNA upregulation in
breast cancers is at a frequency of up to 20% across dif-
ferent studies, in contrast to much lower frequency
alteration of other pro-apoptotic Bcl-2 relatives (Fig. 1a
The Cancer Genome Atlas (TCGA) Breast data25–27 and
METABRIC data28 (not shown)). Of note, while increased
MCL1 was evident, both up- and downregulation of other
family members BCL2, BCL2L1(BCL-XL), BCL2A1(A1)
and BCL2L2(BCL-W) were observed. These data suggest
an exquisite role for upregulated MCL1 in breast cancer.
Interestingly, MCL1 mRNA levels were found to inversely
correlate with BCL2 (Fig. 1b and Supplementary Fig. 1)
upon analysis of two large independent breast cancer data
sets26,27,29. Positive correlation was observed between
MCL1 and BCL2A1 mRNA while correlations with other
pro-survival Bcl-2 proteins were not consistent between
data sets (Fig. 1b and Supplementary Fig. 1). Unlike the
relatively stable proteins BCL-2 and BCL-XL, MCL-1 has
a very short half-life under normal conditions and thus a
functional role for elevated MCL-1 may further manifest
at the protein level. We, therefore, analysed MCL-1 pro-
tein expression by immunohistochemistry in a large
tumour tissue microarray of 428 patients with primary
operable breast cancer, and correlated MCL-1 expression
with associated clinicopathological data (see Table 1 30).
MCL-1 expression was detected in almost every tumour.
Using a weighted histoscore method, which captures
intensity of staining as well as percentage of cell positiv-
ity31, a broad range of MCL-1 protein level in tumour
epithelium was observed in different patient samples
(Fig. 1c). While no correlation was observed between
MCL-1 protein level and age of patient at diagnosis
(Fig. 1d), we discovered a statistically signiﬁcant shift in
MCL-1 with increased tumour size, invasive grade and in
cases where tumour had spread to lymph nodes (Fig. 1e-g,
*P ≤ 0.05, **P ≤ 0.01 Pearson Chi-Square test). Consistent
with these ﬁndings, high MCL-1 protein expression was
found to correlate with poor patient prognosis P= 0.005
(Log-rank Mantel-Cox) (Fig. 1h).
MCL-1 protein expression is important within speciﬁc
breast cancer subtypes
MCL1 mRNA is higher in Basal (including Claudin-low
(CL)) breast cancers relative to other subtypes (Fig. 2a, b)
and we reasoned that MCL-1 may have differential
prognostic signiﬁcance in certain subtypes of breast can-
cer. Although within our TMA a similar range in MCL-1
protein level was apparent across ER-negative and ER-
positive breast cancers, MCL-1 high cases in both groups
appeared to have poorer prognosis than MCL-1 low cases
(Fig. 2c-e). MCL-1 protein was signiﬁcantly elevated in
ERBB2 ampliﬁed (ERBB2 positive) breast cancers (Fig. 2f)
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but intriguingly, did not signiﬁcantly correlate with
prognosis (Fig. 2h) and rather, exclusion of ERBB2-
positive cases potentiated the association between high
MCL-1 and poor prognosis P= 0.007 (Log-rank Mantel-
Cox test), with 10 year survival now being stratiﬁed
from 82 to 71% (Fig. 2g). Triple-negative (TN; i.e., ER/PR/
Fig. 1 (See legend on next page.)
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ERBB2 negative) breast cancers are considered among the
most aggressive of breast cancers and have no targeted
treatment options. Although MCL-1 protein levels were
comparable between TN and non-TN subtypes (Fig. 2i),
MCL-1 high TN breast cancer patients showed the worst
overall prognosis of all, P= 0.042 (Log-rank Mantel-Cox
test) (Fig. 2j, k) with only 64% survival at 10 years vs. 77%
for MCL-1 low TN cases. These ﬁndings emphasise the
prognostic importance of MCL-1 protein expression in
breast cancer.
MCL-1 is required for breast cancer cell-line survival in vitro
MCL-1 protein expression has been shown in a wide
range of breast cancer cell lines23,24. In agreement with
this, we detected MCL-1 in cell lines representing the
main subtypes of breast cancer (Fig. 3a). MDA-MB-468
cells were selected for further study as they expressed
relatively high levels of MCL-1 and as a TN breast cancer
cell line they are representative of a disease subtype that is
in need of new therapies. Consistent with previous stu-
dies22–24 we found that MDA-MB-468 cells depend on
MCL-1 for survival in vitro as the MCL-1 targeted BH3-
mimetic inhibitors UMI-77 (Fig. 3b) and A1210477
(Fig. 3c) reduce viability of MDA-MB-468 cells in a dose-
dependent manner. Sensitivity to MCL-1 inhibition was
also observed in the ER-positive cell line MCF-7, although
only at a higher dose (10 μM) (Supplementary Fig. S2A).
Importantly, we ﬁnd that this results from on-target
effects of these drugs through engagement of the intrinsic
apoptotic pathway as evidenced by induction of PARP
cleavage (Fig. 3d) and caspase 3 activation that requires
the presence of BAX/BAK (Fig. 3e and Supplementary
Fig. S2B). Furthermore, MCL-1 inhibitor mediated cell
death was abrogated by caspase inhibition with Q-VD-
OPh (Fig. 3f, g) again showing on-target impact of these
BH3-mimetics in breast cancer cells.
Targeting MCL-1 restricts growth of TN breast cancer
xenografts
As treatment with MCL-1 targeting BH3-mimetic drugs
induced apoptosis of breast cancer cells in vitro we tested
the in vivo potential of such drugs. To clinically model
breast cancer treatment we commenced pharmaceutical
intervention once xenograft tumours had become clini-
cally detectable. To this end, MDA-MB-468 breast cancer
cells were injected into the mammary fat pads of BALB/c-
Nude mice. Tumours were allowed to establish and when
they reached ~ 5mm diameter, treatment with the MCL-
1-speciﬁc inhibitor UMI-77 (60 mg/kg) or vehicle control
commenced by intraperitoneal injection 5 times per week.
(see ﬁgure on previous page)
Fig. 1 High levels of MCL-1 protein predict poor outcome in breast cancer. a cBioportal analysis of pro-survival Bcl-2 family member gDNA and
mRNA level using25 TCGA Breast Invasive Carcinoma data set. Unaltered cases not shown, n = 816 patients. The results shown in Fig. 1a are in the
whole based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. b Scatterplots of MCL1 mRNA expression vs. BCL2,
BCL2L1 (BCL-xL), BCL2A1 and BCL2L2 (BCL-W) in combined Affymetrix data set of 2999 breast tumours29 P < 0.05; R > 0.03. c Representative MCL-1
immunohistochemistry images on primary operable breast tumour tissue microarray cores depicting low epithelium MCL-1 staining (left panels) and
MCL-1 high (right panels). Scale bar = 100 μm, boxed areas in upper panels are shown at higher magniﬁcation in lower panels. d-g Comparison of
MCL-1 protein levels in patient cohort by d age at diagnosis, e tumour size in mm, f tumour grade, g lymph node (LN) status where 0 = no tumour
detected in lymph nodes and 1 = tumour detected in at least 1 lymph node. Each point represents the average MCL-1 histoscore of an individual
patient from 2–3 independent biopsy cores and bars indicate mean ± SD * P < 0.05, **P < 0.01, Pearson Chi-Square test. h Kaplan–Meier survival plot
of breast cancer-speciﬁc survival by MCL-1 protein level determined by histoscore, n = 420 patients, P = 0.005 Log-rank (Mantel-Cox) test
Table 1 Clinicopathological characteristics of patients with primary operable breast cancer
Clinicopathological characteristics (total) Patients (n%)
Age (≤50/≥51 years) (n=428) 141 (33%)/287 (67%)
Size (mm ≤20/>20) (n=427) 212 (50%)/215 (50%)
Tumour type (special type/lobular/ductal) (n=428) 24 (6%)/23 (5%)/381 (89%)
Grade (I/II/III) (n=426) 55 (13%)/176 (41%)/195 (46%)
Involved lymph node (Negative/positive) (n=420) 231 (55%)/189 (45%)
Oestrogen receptor status (ER-/ER+) (n=428) 182 (43%)/246 (57%)
Progesterone receptor status (PR-/PR+) (n=428) 259 (61%)/169 (39%)
ERBB2 ampliﬁcation status (ERBB2-/ERBB2+) (n=426) 336 (78%)/90 (21%)
TN status (ER-,PR-,ERBB2-/ER+,PR+,ERBB2+) (426) 118 (28%)/308 (72%)
MCL-1 (High/low) (n=428) 220 (51%)/208 (49%)
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Fig. 2 (See legend on next page.)
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Treatment with UMI-77 signiﬁcantly delayed growth of
established MDA-MB-468 xenografts (Fig. 4a). After
4 weeks of treatment, tumours were harvested and
tumour reduction conﬁrmed and further quantiﬁed
(Fig. 4b and Supplementary Fig. S3A). Low levels of
apoptosis were detected in the excised tumours by
immunohistochemistry for cleaved caspase 3 (Fig. 4c)
while a signiﬁcant increase was seen in the UMI-77-
treated tumours (Fig. 4d) consistent with the on target
effects of UMI-77 in MCL-1 inhibition and induction of
apoptosis that we observed in vitro (Fig. 3d, e). To conﬁrm
this requirement for MCL-1 in breast cancer growth, a
second in vivo approach was taken whereby MDA-MB-
468 cells were treated with control siRNA or Mcl1-spe-
ciﬁc siRNA (Supplementary Fig. S3B) prior to injection
into mammary fat pads of BALB/c-Nude mice. Tumour
growth was monitored following injection and knock-
down of MCL-1 was shown to substantially impair
tumour growth (Fig. 4e, f). Interestingly when end-stage
tumours were harvested, MCL-1 expression had recov-
ered (Supplementary Fig S3C, D), which reinforces that
MCL-1 inhibition transiently during early tumour devel-
opment can still impact on tumour growth but that
selection for presence of MCL-1 ultimately occurs. These
ﬁndings verify the requirement for MCL-1 in TN breast
cancer growth in vivo.
Mcl1 is required for mammary tumour development in vivo
The associations between high MCL-1 and poor out-
come, along with the observed frequent ampliﬁcation of
MCL1 in breast cancer may reﬂect a requirement for
MCL-1 in the oncogenic process as has been observed in
haematopoietic cancers32–35. To deﬁnitively test this
hypothesis we utilised a genetic mouse model of breast
cancer. The MMTV-PyMT mouse recapitulates features
of human breast cancer progressing through hyperplasia
to metastasis36 in which we ﬁnd high levels of MCL-1 in
primary and metastatic lesions (Fig. 5a) and are able to
genetically manipulate Mcl1. We tested the impact of
reduction (heterozygous loss, HET) or deletion (homo-
zygous loss, HOM) of MCL-1 on tumour development
and metastatic spread in this model by utilising MMTV-
Cre to drive speciﬁc deletion of Mcl1ﬂ/ﬂ in the mammary
epithelium of female MMTV-PyMT mice (Supplementary
Fig. S4A). Mice of all genotypes were monitored for
tumour development (blinded for genotype), and when
tumours reached clinical endpoint, mammary tumours
and lungs were harvested for analysis. Tumour related
survival, number of lung metastases, and other parameters
of tumour development were all comparable between
mice regardless of whether mice were bred to express
mammary-speciﬁc deletion of Mcl1 or not (Fig. 5b, c and
Supplementary Fig. S4). Surprisingly, immunohisto-
chemical analysis revealed that both WT and HOM
tumours expressed equally high levels of MCL-1, whereas
a range of MCL-1 expression was observed in early
mammary lesions in the HOM mice (Fig. 5d). These data
suggest a selective pressure in mammary tumorigenesis
against loss of MCL-1 and that tumour outgrowth is the
result of escaper cells retaining expression of MCL-1,
probably due to the MMTV-Cre not efﬁciently deleting
the gene in all mammary cells. To address this we utilised
a conditional ROSA-tdRFP reporter allele37 as a surrogate
for MMTV-Cre expression. This supported our hypoth-
esis of a selective pressure against loss of MCL-1: while 6
of 7 WT mice and 11 of 11 HET mice developed RFP-
positive tumours, only 2 of 8 HOM mice developed any
RFP-positive tumours (Fig. 5e, f). Furthermore, in the two
HOM mice where RFP-positive tumours were detected,
RFP positivity was restricted to small areas and only
occurred in a minority of tumour burdened glands (see
example in Fig. 5g, and compared to HET in Fig. 5f).
Importantly, immunohistochemical analysis on serial
sections of RFP-positive areas of tumours from HOM
mice revealed equivalent levels of MCL-1 protein to
neighbouring cells that were RFP negative (Fig. 5h, i).
Therefore, these rare populations of tumour cells (that
had tolerated Cre activation while harbouring Mcl1ﬂ/ﬂ
alleles) had emerged with MCL-1 expression intact.
Altogether these data clearly indicate strong selective
pressure against Mcl1 gene loss and an absolute
requirement for MCL-1 in mammary tumorigenesis.
Discussion
Here, we report an association between high MCL-1
protein expression in tumour epithelium and poor patient
(see ﬁgure on previous page)
Fig. 2 MCL-1 level is important within speciﬁc breast cancer subtypes. a Comparison of MCL1 mRNA expression across 2999 breast tumours29
segregated into subtypes56, Basal/CL (claudin low) n = 296, ERBB2 n = 716, Luminal n = 1959 and Normal-like, n = 28, Wilcoxon test Basal/CL v rest P =
7e-10. b Comparison of MCL1 mRNA expression across 1904 breast tumours28 segregated into PAM50 + CL subtypes, Basal/CL n = 398, ERBB2 n = 220,
Luminal A n = 697, Luminal B n = 461, Normal-like n = 140, Wilcoxon test Basal/CL v rest P = 6e-11. c–k Comparison of MCL-1 protein levels in patient
cohort by c–e ER status, n = 181 ER negative, n = 246 ER positive; f–h ERBB2 status, n = 335 ERBB2 negative, n = 90 ERBB2 positive; i–k Triple-negative
(TN) status, n = 118 TN, n = 308 non-TN. For c, f, i each point represents the average MCL-1 histoscore of an individual patient from 2–3 independent
biopsy cores and bars indicate mean ± SD **P < 0.01, unpaired t-test. For Kaplan–Meier graphs, data are plotted for patients where follow-up data
were available. Kaplan–Meier survival plots of breast cancer-speciﬁc survival segregated by MCL-1 protein level are shown d, e, g, h, j, k and P-values
indicated on plots, Log-rank (Mantel-Cox) test. Black line indicates MCL-1 low cases and red line MCL-1 high cases
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Fig. 3 MCL-1 is required for breast cancer cell line survival in vitro. a Western blot analysis of MCL-1 protein expression across a panel of human
breast cancer cell lines. b, c MTS assay showing viability of MDA-MB-468 cells after 48 h treatment with indicated dose of MCL-1 inhibitor (b) UMI-77
or (c) A1210477. Bars indicate mean ± SD, of n = 3–5 independent experiments plated in triplicate. d Western blot showing full length (FL) and
cleaved (cl) PARP following incubation of MDA-MB-468 cells with indicated doses of UMI-77 for 24 h. Actin as loading control shown below. e
Western blot analysis (as for d) showing PARP cleavage and active caspase 3 (CC3) in MDA-MB-468 CRISPR/Cas9 edited for BAX/BAK deletion (see
Supplementary Fig. S2B) or non-targeting control following 24 h treatment with 10 μM UMI-77 or 10 μM etoposide (etopo). Actin loading control is
given for each membrane. f, g Incucyte Sytox Green cell death assay of cell lines described in e following 48 h treatment with 5 μM A1210477 (f) and
0.1 μM S63845 (g) in the presence or absence of 10 μM Q-VD-OPh caspase inhibitor. Cell death was calculated with the formula CDtreatment-CDbasal
where CDtreatment is Sytox Green cells/cell conﬂuence following 48 h treatment with MCL-1 inhibitor and CDbasal is Sytox Green cells/cell conﬂuence
in control samples at 48 h. Graph represents mean ± SEM from n = 3–4 independent experiments plated in triplicate
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outcome in breast cancer. This work signiﬁcantly
enhances our knowledge about the prognostic value of
MCL-1 protein in breast cancer. Early studies of breast
cancer patient cohorts reported opposing results when
assessing MCL-1 expression; one study found no asso-
ciation between MCL-1 protein expression and patient
outcome38, while another linked high MCL-1 protein with
high tumour grade and poor outcome39. The contrasting
ﬁndings of these studies (notably with smaller patient
numbers of 170 and 125, respectively), with no separation
by disease subtype could be explained if a prognostic role
for MCL-1 occurred only in particular subsets of patients.
More recently, MCL-1 was shown to be widely expressed
in breast tumours, regardless of subtype or ER status10,24
although these studies did not report patient outcome.
Intriguingly, low levels of MCL-1 protein were correlated
with poor prognosis in a cohort of Luminal A breast
cancer patients24. The same study reported differential
associations between MCL1 mRNA levels and prognosis
depending on whether patients had received treatment. At
Fig. 4 Targeting MCL-1 restricts triple-negative breast cancer cell growth in vivo. a Inhibition of MDA-MB-468 tumour growth in orthologous
transplantation assay in response to MCL-1 inhibitor UMI-77. Treatment commenced when tumours were ~5mm diameter. Graph represents weekly
average tumour volume ± SEM, n = 13 vehicle-treated (black line) and n = 14 UMI-77 treated (red line) *P≤ 0.05 (Students t-test). b Representative
photograph of vehicle (upper) or UMI-77 (lower)-treated tumours (as in a) harvested at end of experiment (after 4 weeks treatment), for weights of all
tumours see Supplementary Fig. S3A. c Immunohistochemical analysis of cleaved caspase 3 expression in tumours harvested 4-weeks post-treatment.
Representative images shown; n = 11–12 for each group. Scale bar is 100 μm. d Quantiﬁcation of cleaved caspase 3 in orthologous tumours
harvested 4-weeks post-treatment; bars indicate mean ± SEM and points represent average cleaved caspase 3 staining per tumour *P≤ 0.05
(unpaired t-test) n = 12 vehicle-treated tumours and n = 11 UMI-77-treated tumours. Results are expressed as proportion of brown pixels (cleaved
caspase 3 IHC stain) to blue pixels (nuclear stain) from 3–4 ﬁelds of view (on 10X objective) per tumour, quantiﬁed using Adobe photoshop 5.1. e
Inhibition of MDA-MB-468 tumour growth in orthologous transplantation assay following siRNA knockdown of MCL1. Graph represents tumour
volume from date of transplantation. Weekly average of n = 16 siControl (black line) and n = 15 siMCL1 (red line) tumours is shown ± SEM *P≤ 0.05
(unpaired t-test). f Reduced weight of siMCL1 tumours harvested after 3 weeks growth in vivo, n = 10 tumours per condition harvested at this
timepoint. Points indicate individual tumour weights and bars are mean ± SD *P≤ 0.05 (unpaired t-test)
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the time of sampling, all of the patients in our study were
treatment naive and the subsequent use of hormone
therapy was almost universal across our ER+ cohort.
Differences in treatment exposure at time of sampling
could potentially account for these disparate ﬁndings as
expression of Bcl-2 family proteins, including MCL-1, are
known to be altered in response to therapy3,40. Here, we
can conﬁrm the prognostic potential of MCL-1 at initial
patient presentation.
In our study all subtypes are well represented and
extensive clinicopathological data was available allowing
fuller interrogation. Indeed, while we found an overall
association between high MCL-1 and poor prognosis
across our entire cohort (Fig. 1h), segregation of cases by
receptor status (ER/HER2) revealed that although ERBB2/
HER2 ampliﬁed tumours expressed high levels of MCL-1
protein, patient outcome was not dictated by MCL-1
expression in this subtype (Fig. 2). Interestingly induction
of ERBB2/HER2 expression has been shown to increase
MCL1 mRNA levels in MCF-7 cells41, perhaps explaining
the high level of MCL-1 protein we ﬁnd in ERBB2/HER2-
positive disease and it is possible that while not prog-
nostic, these tumours could still depend on MCL-1 for
survival42 as was indeed observed in a very recent study
from the Lindeman group23. In our cohort, high MCL-1
protein showed similar associations with poor prognosis
when cases were segregated by ER status (Fig. 2) and
within the ER/PR/ERBB2-negative cohort where patients
with high MCL-1 faired worst of all (Fig. 2). Intriguingly,
as no relationship was found between MCL-1 protein and
transcript levels in breast cancer samples38 it suggests to
us that pathways altering MCL-1 translation or protein
stability have an impact on patient survival.
In contrast to our ﬁndings with MCL-1, BCL-2 has been
shown to be a favourable prognostic marker in breast
cancer, often associated with slowly proliferating low
grade ER-positive tumours43–45. High BCL-2 protein
expression predicts favourable outcome regardless of ER,
PR or HER2 status46 however, BCL2 is only expressed in a
small proportion of TN breast cancers7 andMCL1mRNA
is higher than BCL2 or BCL2L1(BCL-XL) across all sub-
types of breast cancer10. We ﬁnd an inverse relationship
between MCL1 and BCL2 mRNA (Fig. 1b and Supple-
mentary Fig. 1A). It is clear that MCL-1 and BCL-2 play
roles in different patient groups and that targeting MCL-1
has the potential to impact on patients with the worst
prognosis, including receptor-negative breast cancer
patients who currently have no targeted treatment
options. Clinical trials are currently investigating ABT-
199/Venetoclax in combination with tamoxifen in ER-
positive metastatic breast cancer (ISRCTN98335443). It
will be interesting to see whether MCL-1 levels correlate
with resistance to Venetoclax in patients, as has been
observed in breast cancer cell lines10.
The prevalence of elevated MCL-1 in breast cancer and
potential for therapeutic intervention shown here and by
others10,23,24 suggests a functional role in early tumour
development. In support of this hypothesis, we found that
MCL-1 expression was necessary for tumour develop-
ment in the MMTV-PyMT mouse model of breast cancer,
with outgrowth of tumours in the context of Mcl1 deﬁ-
ciency only occurring when cells escaped deletion of Mcl1
(Fig. 5). MCL-1 is known to play a role in mammary gland
development, but no selection against MMTV-cre;Mcl1ﬂ/ﬂ
cells deﬁcient for MCL-1 was observed in normal
mammary gland47, indicating a speciﬁc dependence of
(see ﬁgure on previous page)
Fig. 5 MCL-1 is required for mammary tumour development in vivo. a Immunohistochemical analysis showing MCL-1 protein expression at
different stages of mammary tumorigenesis (written above image) evident within a single MMTV-PyMT mouse. Data representative of≥ 4
independent mice. Scale bar is 50 μm. b Kaplan–Meier tumour free survival analysis of MMTV-PyMT; MMTV-Cre transgenic female mice with targeted
deletion of Mcl1 in the mammary epithelium. Median survival of MMTV-PyMT mice with wild-type Mcl1 (WT) 88 days, n = 36; with targeted deletion of
one allele of Mcl1 in the mammary epithelium (HET) 88 days, n = 28; and targeted deletion of both alleles (HOM) 93 days, n = 18. Full cohort and
genotype information available in Supplementary Fig S4. No signiﬁcant differences were observed between genotypes. c Microscopic lung
metastases were counted in haemotoxylin and eosin stained slides of lung cross-sections from cohort mice harvested when primary tumour reached
clinical endpoint. Median number of observed lung metastases was 3.4 (WT; n = 28), 3.3 (HET; n = 27), 4.2 (HOM; n = 18), no signiﬁcant differences
were observed between genotypes. Each point represents an individual cohort animal; mean and standard deviation are shown. d
Immunohistochemical analysis of MCL-1 protein level in representative WT (left) and HOM (middle) tumours showing high levels of MCL-1 regardless
of genotype while early-stage lesions in HOM mice (right) show heterogeneity in MCL-1 level. Data representative of≥ 5 mice of each genotype/
stage. Scale bar is 100 μm. e Pie charts showing proportion of mice with RFP-positive tumours (represented as red) as determined by IVIS imaging at
clinical endpoint. WT (in 6 of 7 mice analysed); HET (in 11 of 11 mice analysed) and HOM (in 2 of 8 mice analysed). Mice scored as positive regardless
of how many tumours in an individual animal scored positive. f Representative IVIS ﬂuorescence imaging of ROSA-tdRFP reporter in mammary gland/
tumours (all ten glands shown and orientated according to site of harvest with gland number 1 at top and number 5 at bottom of image) and lungs
(circled in black dashed line) from HOM-RFP (MMTV-PyMT;MMTV-cre;Mcl1ﬂ/ﬂ;ROSA-tdRFP) and HET-RFP (MMTV-PyMT;MMTV-cre;Mcl1ﬂ/+;ROSA-tdRFP)
mice. Heat map represents ﬂuorescence intensity with yellow being the highest. g Representative IVIS ﬂuorescence imaging of ROSA-tdRFP reporter
in a HOM-RFP mouse scored as RFP positive by IVIS imaging with minimal ﬂuorescence staining. Orientation as described for f. h, i
Immunohistochemical analysis of RFP expression (h) and MCL-1 expression (I) in serial sections of the small RFP-positive lesion indicated by white
box in (g) depicting absence of MCL-1 deletion in RFP-positive cells. Scale bar is 100 μm
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mammary tumour cells on MCL-1. As the MMTV-PyMT
model is regarded as a model for human luminal breast
cancer48, our results reinforce the applicability of target-
ing MCL-1 in ER-positive disease where high MCL-1
correlated with poorer prognosis (Fig. 2).
In agreement with recent studies, we found that tar-
geting MCL-1 in TN breast cancer cells; in our case
using three different BH3-mimetics speciﬁc for MCL-1
(UMI-77, S63845 and A1210477); inhibited TN breast
cancer cell line growth in vitro. Importantly, we show
that this is through induction of apoptosis in a BAX/
BAK and caspase-dependent manner (Fig. 3) validating
the on-target effect of these drugs on mitochondrial-
dependent apoptosis on breast cancer cells. To further
investigate the therapeutic potential of these ﬁndings,
we tested the impact of pharmacological inhibition of
MCL-1 in established mammary tumours in vivo and
found that MCL-1 inhibition or knock-down inhibited
TN breast cancer growth in xenograft experiments
(Fig. 4). In these models targeting MCL-1 constrained
the intrinsic apoptosis pathway and inhibited TN breast
cancer growth. Importantly, xenograft experiments
showed that therapeutic dosing with an MCL-1 inhi-
bitor could retard TN breast cancer growth without any
apparent adverse effects on the mice. This is in line
with recent studies with an additional MCL-1-speciﬁc
BH3 mimetic, S63845, which showed tumour-speciﬁc
cell killing in xenograft models of haematological
cancers16.
We found that high MCL-1 protein at diagnosis pre-
dicts worse patient outcome and identiﬁes patients that
have the potential to respond to MCL-1 inhibition. MCL-
1 expression has already been linked with resistance to
therapy10,40,49. Our ﬁndings suggest this resistance may
not necessarily be acquired in response to therapy, but in
many cases may be innate, due to the required presence of
high MCL-1 in breast cancer development. Aberrations in
MCL1 are the second most frequent genomic occurrence
in treatment-resistant TN breast cancer samples50 and
targeting MCL-1 may induce apoptosis in these tumours.
Indeed in an elegant study published while this manu-
script was under review, Merino et al.23 demonstrated the
potential of MCL-1 inhibition in combination with con-
ventional chemotherapies for increased efﬁcacy in PDX
models of TN and HER2-ampliﬁed breast cancer. This
highlights the possibility of re-sensitising resistant
tumours to therapy. Interestingly, additional studies pro-
vide support for this theory; in vitro experiments show
cell death induction when HER2 inhibition is combined
with targeting MCL-116 and in vivo it has been shown that
AZD1208 (PIM-kinase inhibitor) downregulates MCL-1
expression (among other effects) in TN breast cancer cell
lines to restrict growth when used in combination with
Eribulin51.
Materials and methods
Tissue microarray (TMA)
The tumour tissue microarrays were obtained from
Greater Glasgow and Clyde NHS Biorepository and
represent a retrospective series of primary breast cancer
patients diagnosed between 1995–1998 with available
clinicopathological features and outcome. The arrays were
composed of 0.6 mm3 cores of primary operable breast
tumour material from 2–3 representative areas of tumour
per patient at the time of surgical resection. ER, PR and
HER2 status was conﬁrmed in cores by standard immu-
nohistochemical/in situ hybridisation techniques.
Immunohistochemistry
Immunohistochemistry (IHC) was carried out with
antibodies to MCL-1 (Proteintech, UK), RFP (Rockland,
PA, USA) or Cleaved Caspase 3 (Cell Signaling Tech-
nology, UK). Epitope retrieval was achieved by heating to
98 °C in pH-6 citrate buffer for 25min before proceeding
as per the manufacturers instructions with MCL-1 anti-
body used at a dilution of 1:300 and Cleaved Caspase 3
antibody at 1:500. IHC for cleaved caspase 3 was quan-
tiﬁed with Adobe photoshop 5.1 using the method
described by Lehr and colleagues52.
TMA scoring
MCL-1 immunoreactivity in the cytoplasm of tumour
epithelium was quantiﬁed using a weighted histoscore
method to give a value of 0–300 by K.J.C.31 Ten percent of
total core number was scored by two observers (K.J.C. and
N.F.) independently and blind to the other observers
score. Inter-observer agreement was measured by Inter-
class Correlation Coefﬁcient. All scoring was performed
blind to clinical and pathological data, and cutoff for
MCL-1 high vs. low was set at histoscore of 168 to cut the
group equally without splitting cases with identical scores
into different MCL-1 groups.
Statistical analysis
Statistical signiﬁcance between experimental groups, P
< 0.05, was calculated by Unpaired t-test, two tailed, with
GraphPad Prism version 6.0c (Graphpad Software, CA,
USA). Kaplan–Meier survival curves of breast cancer-
speciﬁc survival were also plotted using GraphPad Prism
version 6.0c and Mantel-Cox (Log-rank) analysis used to
determine signiﬁcant differences in survival. For associa-
tions between MCL-1 expression and clinical parameters
Pearson Chi-Square tests were performed using SPSS
software version 19 (IBM Corp, NY, USA).
Genetically engineered mouse models
Animals were housed in a barriered facility proactive in
environmental enrichment. All work was carried out in
line with the Animals (Scientiﬁc Procedures) Act 1986
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and the EU Directive 2010 and was sanctioned by the
local ethical review process (University of Glasgow).
MMTV-Cre (kindly supplied from WJ Muller, McGill
University), MMTV-PyMT (The Jackson laboratory, ME,
USA), Mcl1tm3Sjk (Mcl1 ﬂ/ﬂ)(The Jackson laboratory, ME,
USA), and ROSA-tdRFP mice (acquired from the Eur-
opean Mouse Mutant Archive (EMMA)) have all been
described previously37,53–55. All mice had been back-
crossed> 7 generations FVB/N and all controls were lit-
termates. Mice were monitored 2–3 times per week for
tumour development, onset was deﬁned when the ﬁrst
tumour was detectable at 5 mm diameter and clinical
endpoint at 15 mm diameter. At endpoint, mice were
sacriﬁced; mammary gland/tumours and lungs were
excised and imaged using the IVIS Spectrum imaging
system (PerkinElmer, MA, USA). Images were analysed
using the IVIS Living Image software. Organs were
weighed before ﬁxation in 10% formalin and embedding
in parafﬁn wax. Microscopic metastases were detected in
haemotoxylin and eosin stained cross-sections of lungs
under 10X magniﬁcation.
Human cell lines
Human cell lines were originally sourced from the
American Type Culture Collection (ATCC) and were
authenticated by Promega GenePrint 10 System (Promega
WI, USA). Cells were maintained at 37 °C with 5% CO2
with 10% fetal bovine serum (FBS), except for in vitro
experiments using A1210477 where FBS level was reduced
to 3% during drug treatment and also in the relevant
control samples. Cell viability was determined by CellTiter
96 MTS assay (Promega) after 48 h incubation with the
indicated concentration of MCL-1 inhibitor UMI-77
(Selleck, UK), S63845 (Apexbio, UK) or A1210477 (Apex-
bio, UK). SYTOX Green (Invitrogen, UK) was used to
identify dead cells and cell conﬂuence measured using the
Incucyte Live Cell Analysis System (Essen Bioscience, UK).
10 μM etoposide (Sigma, UK) was used to induce apoptosis
and 10 μM Q-VD-OPh (Apexbio, UK) was used to block
caspase activity. CRISPR/Cas9 gene editing using the
LentiCRISPRv2 system (Addgene, MA, USA) was per-
formed for BAX and BAK as described previously2.
Western blotting
Standard western blot procedures were used on whole
cell lysates and probed with antibodies speciﬁc to MCL-1
(Proteintech, UK), ACTIN (Sigma, UK), PARP (Cell Sig-
naling, UK), BAK (Cell Signaling, UK), BAX (Santa Cruz,
CA, USA), HSP70 (Cell Signaling, UK), Active Caspase 3
(Cell Signaling, UK).
Xenograft experiments
For assessment of UMI-77 anti-tumour activity in vivo,
3 million MDA-MB-468 breast cancer cells were injected
bilaterally into the inguinal mammary fat pads in 1:1 PBS:
matrigel mix into 8-week BALB/c-Nu female mice
(Charles River, UK). Treatment commenced 2 weeks after
injection and UMI-77 was administered by intraperitoneal
injection at 60 mg/kg in a regime of 5 daily doses followed
by 2 rest days. For in vivo use UMI-77 was dissolved in 5%
DMSO/30% PEG300/ 65% dd H20. Tumour growth was
monitored by caliper measurement three times per week
and volume calculated using the equation ([length×
width2]2). Graphs represent average of three weekly
measurements relative to tumour volume at commence-
ment of treatment. Tumours were harvested after 4 weeks
of treatment.
MCL-1 knockdown was achieved using a pool of pre-
validated siRNA to human MCL-1 s8583 (Ambion/Life
Technologies, UK) at 5 nM concentration or non-
targeting control siRNA and nucleofection using Amaxa
kit (Lonza, UK) according to the manufacturer's protocol.
For orthologous transplantation assay of siRNA-treated
MDA-MB-468 cells, 3 million siMcl1 or siSCR treated
cells in a 1:1 PBS:matrigel mix were injected bilaterally
into the inguinal mammary fat pads of 6 week female
BALB/c-Nu mice (Charles River, UK) 18 h after
nucleofection.
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